Making a difference with your help.
Protocol Name: SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS Protocol #: TVTX-RE021-426 Indication: Cardiovascular Event Risk Reduction GFR: ≥25 Principal Investigator: Bernard Fischbach, MD, CCRP Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: AZURE: Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event Protocol #: D7960C00015 Indication: Cardiovascular Event Risk Reduction GFR: ≥15 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,
Protocol Name: ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD Protocol #: ALN-AGT01-008 Indication: HTN (Uncontrolled) GFR: <60 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: A study to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients with primary FSGS or minimal change disease Protocol #: ACT18064 Indication: Fabry Disease GFR: ≥ 45 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients Protocol #: CLI-06657AA1-10 (MODERN) Indication: Fabry Disease GFR: n/a Principal Investigator: Ankit N. Mehta, MD, FASN Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients Read More »
Protocol Name: CV Outcomes Study with CSL300 (Clazakizumab) in Adults with ESKD Undergoing Dialysis (POSIBIL6ESKD) Protocol #: CSL300_2301 (POSIBIL6ESKD) Indication: Dialysis GFR: n/a Principal Investigator: Bernard Fischbach, MD, CCRP Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: AZD7760 Safety & PK in Adults with End-stage Kidney Disease on Hemodialysis with a Central Venous Catheter Protocol #: D7480C00001 PEAK Indication: Dialysis GFR: n/a Principal Investigator: Kim M. Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Protocol #: M25-147 ANCHOR Indication: Autosomal Dominant Polycystic Kidney Disease GFR: ≥30 Principal Investigator: Michael R. Wiederkehr, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000,
Protocol Name: Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype Protocol #: MZE829-201 Indication:APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 Principal Investigator: Tapan J. Patel, MD, FACP, FASN, FNKF Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,
Protocol Name: ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome Protocol #: 22419 Indication: Alport Syndrome GFR: ≥45 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS